BioPharma Dive November 20, 2024
Valora Therapeutics, which raised $30 million in seed funding, is built upon research by Stanford scientist Carolyn Bertozzi and MIT researcher Jessica Stark.
Immunotherapy has transformed cancer care over the past decade, thanks to the advent of “checkpoint inhibitors,” which block a common way tumors are able to evade the body’s immune defenses.
The drugs’ name relates to the proteins they target. Signaling between these proteins — found on the surface of immune and tumor cells — can keep an immune cell from recognizing and destroying a malignant one.
Valora Therapeutics, which emerged from stealth Wednesday with $30 million in seed funding, is taking aim at a different kind of checkpoint. Rather than proteins, Valora is focusing on sugar molecules...
Today's Sponsors
Today's Sponsor